(NASDAQ: LXEO) Lexeo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.26%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.21%.
Lexeo Therapeutics's earnings in 2026 is -$87,501,000.On average, 12 Wall Street analysts forecast LXEO's earnings for 2026 to be -$92,906,797, with the lowest LXEO earnings forecast at -$110,040,218, and the highest LXEO earnings forecast at -$81,623,239. On average, 11 Wall Street analysts forecast LXEO's earnings for 2027 to be -$102,604,219, with the lowest LXEO earnings forecast at -$130,817,042, and the highest LXEO earnings forecast at -$70,080,558.
In 2028, LXEO is forecast to generate -$98,112,782 in earnings, with the lowest earnings forecast at -$143,129,234 and the highest earnings forecast at -$48,644,152.